MALVERN, Pa. - Ocugen, Inc. (NASDAQ: NASDAQ:OCGN), a biotechnology company known for its work in gene and cell therapies and vaccines, today announced the appointment of Dr. Huma Qamar as its new Chief Medical Officer (CMO).
Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen, expressed his pleasure in naming Dr. Qamar to the position, highlighting her significant contributions to the company's clinical team and her role in a successful Phase 1/2 gene therapy trial.
Dr. Qamar brings to the role a wealth of experience from her time at prestigious Ivy League institutions, such as Yale, Harvard, and the University of Pennsylvania. Her background includes developing clinical protocols for Phase I-IV studies, leading medical affairs teams, and managing FDA inspections. Dr. Qamar has been with Ocugen for over three years and has expressed her commitment to advancing the company's clinical development and addressing patient needs by bringing new gene therapy products to the global market.
Her expertise spans a range of therapeutic areas, including gene and cell therapy, vaccines, and oncology, among others. Dr. Prabhavathi Fernandes, Independent Lead Director on the Ocugen board, voiced confidence in Dr. Qamar's ability to lead the company's first-in-class candidates through upcoming clinical milestones and contribute to Ocugen's long-term strategy.
Before her tenure at Ocugen, Dr. Qamar served as Senior Vice President, Head of R&D at FSD Pharma, where she continued her dedication to scientific innovation and pharmaceutical development.
Ocugen's mission is to develop therapies and vaccines to improve health and provide hope for patients worldwide. The company's modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and it is also advancing research in infectious diseases and orthopedic diseases to meet unmet medical needs.
The information in this article is based on a press release statement from Ocugen, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.